血液和骨髓移植临床研究网络：自 2007 年科学研讨会以来的进展。
Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.
机构信息
Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
出版信息
Biol Blood Marrow Transplant. 2014 Feb;20(2):149-53. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.
Abstract
Outcomes of hematopoietic cell transplantation continue to improve. New techniques have reduced transplant toxicities, and there are new sources of hematopoietic stem cells from related and unrelated donors. In June 2007, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) convened a State of the Science Symposium (SOSS) in Ann Arbor and identified 11 high priority clinical trials for the network to pursue. This article reviews both the status of those trials and the record of achievement of the BMT CTN as it convenes another SOSS in Grapevine, Texas in February 2014.
摘要
造血细胞移植的疗效不断提高。新技术降低了移植的毒性，也有来自亲缘和非亲缘供者的新的造血干细胞来源。2007 年 6 月，血液和骨髓移植临床研究网络（BMT CTN）在安阿伯举行了一次科学状况研讨会（SOSS），确定了该网络需要进行的 11 项优先临床试验。本文回顾了这些试验的现状以及 BMT CTN 的成就，因为该网络于 2014 年 2 月在德克萨斯州的 Grapevine 再次召开了 SOSS。
相似文献
1
Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.血液和骨髓移植临床研究网络：自 2007 年科学研讨会以来的进展。
Biol Blood Marrow Transplant. 2014 Feb;20(2):149-53. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.
2
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.2007年血液与骨髓移植临床试验网络科学现状研讨会
Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-85. doi: 10.1016/j.bbmt.2007.08.005.
3
Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.造血细胞移植临床医生的实践模式与偏好
Biol Blood Marrow Transplant. 2016 Nov;22(11):2092-2099. doi: 10.1016/j.bbmt.2016.07.014. Epub 2016 Jul 29.
4
Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.将患者和照护者的声音纳入临床试验合唱团：来自 BMT CTN 患者和照护者倡导工作组的报告。
Transplant Cell Ther. 2023 Jan;29(1):5-9. doi: 10.1016/j.jtct.2022.10.016. Epub 2022 Oct 23.
5
Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization.临床研究向实践的转化：对血液和骨髓移植临床试验网络方案 0201 对非亲缘供者移植源利用结果的影响评估。
Biol Blood Marrow Transplant. 2018 Nov;24(11):2204-2210. doi: 10.1016/j.bbmt.2018.06.028. Epub 2018 Jun 30.
6
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.血液和骨髓移植临床研究网络 2021 年科学研讨会：展望未来，网络迎来成立 20 周年。
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
7
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.血液与骨髓移植临床试验网络：解决造血细胞移植重要问题的有效基础设施。
Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.
8
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植
Cochrane Database Syst Rev. 2014 Apr 20;2014(4):CD010189. doi: 10.1002/14651858.CD010189.pub2.
9
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.非血缘供者移植后经减低强度预处理：使用部分 HLA 错配相关骨髓或无关双脐血移植物的平行 2 期试验结果。
Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.
10
Designing and conducting a clinical trial in blood and marrow transplantation.设计和开展血液和骨髓移植临床试验。
Best Pract Res Clin Haematol. 2023 Jun;36(2):101471. doi: 10.1016/j.beha.2023.101471. Epub 2023 May 11.
引用本文的文献
1
TCF-1 Is Required for CD4 T Cell Persistence Functions during AlloImmunity.TCF-1 在同种异体免疫中 CD4 T 细胞持久功能中是必需的。
Int J Mol Sci. 2023 Feb 21;24(5):4326. doi: 10.3390/ijms24054326.
2
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.TCF-1 在抗肿瘤反应中调节 CD8 T 细胞上的 NKG2D 表达。
Cancer Immunol Immunother. 2023 Jun;72(6):1581-1601. doi: 10.1007/s00262-022-03323-0. Epub 2022 Dec 23.
3
Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.靶向SLP76:ITK相互作用可在异基因造血干细胞移植中区分移植物抗宿主病与移植物抗白血病效应。
iScience. 2021 Mar 11;24(4):102286. doi: 10.1016/j.isci.2021.102286. eCollection 2021 Apr 23.
4
Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.靶向白细胞介素 2 诱导的 T 细胞激酶（ITK）可区分同种异体 HSCT 中的移植物抗白血病效应和移植物抗宿主病。
Front Immunol. 2020 Nov 26;11:593863. doi: 10.3389/fimmu.2020.593863. eCollection 2020.
5
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.血液与骨髓移植临床试验网络：解决造血细胞移植重要问题的有效基础设施。
Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.
6
Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries.日本及其他国家造血干细胞移植数据登记处的质量控制与保证
Int J Hematol. 2016 Jan;103(1):20-4. doi: 10.1007/s12185-015-1896-8. Epub 2015 Nov 13.
7
NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.在同种异体造血干细胞移植的小鼠模型中，CD8 + T细胞的NKG2D表达有助于移植物抗宿主病（GVHD）和移植物抗肿瘤（GVT）效应。
Blood. 2015 Jun 4;125(23):3655-63. doi: 10.1182/blood-2015-02-629006. Epub 2015 Mar 18.
8
Blood and marrow transplant clinical trials network state of the Science Symposium 2014.2014年血液与骨髓移植临床试验网络科学研讨会
Biol Blood Marrow Transplant. 2015 Feb;21(2):202-24. doi: 10.1016/j.bbmt.2014.10.003. Epub 2014 Oct 15.
9
Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation.参与临床研究：接受造血干细胞移植的成年患者及儿科患者家长的观点
Biol Blood Marrow Transplant. 2014 Oct;20(10):1604-11. doi: 10.1016/j.bbmt.2014.06.020. Epub 2014 Jun 24.
本文引用的文献
1
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.多中心研究使用第三方储存的病毒特异性 T 细胞治疗造血干细胞移植后严重病毒感染。
Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.
2
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.非亲缘供者造血细胞移植治疗噬血细胞性淋巴组织细胞增生症
Bone Marrow Transplant. 2008 Aug;42(3):175-80. doi: 10.1038/bmt.2008.133. Epub 2008 May 5.
3
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.异基因细胞毒性T细胞疗法治疗EBV阳性移植后淋巴细胞增殖性疾病：一项2期多中心临床试验的结果
Blood. 2007 Aug 15;110(4):1123-31. doi: 10.1182/blood-2006-12-063008. Epub 2007 Apr 27.
4
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.高剂量免疫抑制疗法及自体造血细胞移植治疗重症系统性硬化症：美国多中心试点研究的长期随访
Blood. 2007 Aug 15;110(4):1388-96. doi: 10.1182/blood-2007-02-072389. Epub 2007 Apr 23.
5
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.细胞遗传学对首次或第二次完全缓解的急性髓系白血病患者单倍体相合无关供者造血干细胞移植结局的影响
Blood. 2007 Jul 1;110(1):409-17. doi: 10.1182/blood-2006-10-043299. Epub 2007 Mar 20.
6
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.基于梅奥骨髓瘤分层和风险适应性治疗（mSMART）的新诊断多发性骨髓瘤治疗：共识声明
Mayo Clin Proc. 2007 Mar;82(3):323-41. doi: 10.4065/82.3.323.
7
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?HOVON/SAKK对年轻及中年成人首次缓解期急性髓系白血病患者进行清髓性 HLA 全相合同胞干细胞移植时供者与非供者分析的结果：对谁有益？
Blood. 2007 May 1;109(9):3658-66. doi: 10.1182/blood-2006-06-025627. Epub 2007 Jan 9.
8
New prognostic markers in CLL.慢性淋巴细胞白血病的新预后标志物
Hematology Am Soc Hematol Educ Program. 2006:279-84. doi: 10.1182/asheducation-2006.1.279.
9
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation.调节性T细胞迁移和存活的体内动力学预测了控制异基因移植后移植物抗宿主病的有效策略。
Blood. 2007 Mar 15;109(6):2649-56. doi: 10.1182/blood-2006-08-044529. Epub 2006 Nov 9.
10
Hemophagocytic lymphohistiocytosis and related disorders.噬血细胞性淋巴组织细胞增生症及相关疾病。
Curr Opin Allergy Clin Immunol. 2006 Dec;6(6):410-5. doi: 10.1097/01.all.0000246626.57118.d9.
Zotero 插件